Özge Özgen Top

ORCID: 0000-0003-1468-4960
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Antibiotic Resistance in Bacteria
  • Antibiotics Pharmacokinetics and Efficacy
  • Bacterial Identification and Susceptibility Testing
  • Respiratory viral infections research
  • Infections and bacterial resistance
  • Pancreatic and Hepatic Oncology Research
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Influenza Virus Research Studies
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Antibiotic Use and Resistance
  • Vector-borne infectious diseases
  • Viral Infections and Vectors
  • Herpesvirus Infections and Treatments
  • Autoimmune Bullous Skin Diseases
  • Urinary Tract Infections Management

Gazi University
2022-2025

Abstract Background The varicella-zoster virus induces a primary infection known as varicella (chickenpox) and subsequently becomes latent in the dorsal root or cranial nerve ganglia. Later life, may reactivate, leading to secondary called herpes zoster (shingles). Despite increasing population at risk, research on shingles Türkiye is limited. This study aimed assess clinical demographic characteristics of risk factors for postherpetic neuralgia among adults Türkiye.Table 1.Demographic...

10.1093/ofid/ofae631.2485 article EN cc-by Open Forum Infectious Diseases 2025-01-29

Background/aim: Ralstonia species are opportunistic, waterborne microorganisms known for their ability to survive and proliferate in a wide range of water-based environments. They can contaminate solutions used patient care cause hospital outbreaks due contaminated solutions. The aim this study was investigate the source clonal relationship insidiosa bacteremia detected 28 patients between August December 2021, as part an unusual outbreak.Materials methods: Active prospective surveillance...

10.55730/1300-0144.5967 article EN cc-by TURKISH JOURNAL OF MEDICAL SCIENCES 2025-02-18

The study aimed to compare polymyxin B with colistimethate sodium (CMS) regarding neurotoxicity, nephrotoxicity and 30-day mortality in patients MDR Gram-negatives. All adult who received or CMS for at least 24 h the treatment of microorganisms were evaluated retrospectively. Among 413 initially screened patients, 147 conscious able express their symptoms included neurotoxicity analysis. 13 77 1 70 had neurotoxic adverse events, mainly paresthesias. events reversible after drug...

10.1186/s12879-024-09759-2 article EN cc-by-nc-nd BMC Infectious Diseases 2024-08-26

The aim of the study was to evaluate clinical and microbiological efficacy safety intravenous fosfomycin for treatment carbapenem-resistant K. pneumoniae infections. All adult inpatients receiving 48 h fosfomycin, alone or combined with other antibiotics were included in study. Overall favorable response rate 75.3% among 94 patients. Clinical rates 92.3%, 72.2% 56.0% urinary tract infections, bacteremia pneumonia, respectively. Microbiological eradication achieved 55 86 30-day mortality...

10.1080/1120009x.2022.2149186 article EN Journal of Chemotherapy 2022-11-22

Objective: Influenza is among the most important respiratory infections affecting all age groups and can lead to hospitalizations. We aimed determine frequency of influenza acute admissions with influenza-like illness (ILI) evaluate demographic, clinical findings, outcomes patients influenza.

10.36519/idcm.2023.285 article EN cc-by-nc Infectious Diseases and Clinical Microbiology 2023-12-29

Objective: There are many difficulties in diagnosing and treating Stenotrophomonas maltophilia bacteremia. In this study, we aimed to evaluate “true” “false-positive bacteremia” assess mortality risk factors the impact of different treatment regimens. Materials Methods: Hospitalized adult patients with S. maltophilia-positive blood cultures were assessed by a two-stage analysis. First, clinical significance was assessed, divided into groups. Then, excluding false positives, analyzed...

10.36519/idcm.2022.187 article EN cc-by-nc Infectious Diseases and Clinical Microbiology 2022-12-21
Coming Soon ...